Isomorphic Labs

Isomorphic Labs, led by CEO Sir Demis Hassabis and President Max Jaderberg, is transforming drug discovery with the power of artificial intelligence and ushering in a new era of biomedical breakthroughs.

Isomorphic Labs has built a world-leading AI drug design engine comprising foundational AI models that are capable of working across multiple therapeutic areas and drug modalities. The company is continually innovating on model architecture and developing cutting-edge capabilities to advance drug design.

Isomorphic Labs is headquartered in London and has office locations in Cambridge, Massachusetts and Lausanne, Switzerland. Isomorphic Labs is advancing a broad and ambitious drug design portfolio through partnered programs and wholly-owned internal programs.